What are the key issues women face when ending hormone replacement therapy?
Wulf H. Utian, MD, BCH, PhD
Department of Obstetrics and Gynecology, The Cleveland Clinic; Professor Emeritus, Case Western Reserve University; Executive Director, The North American Menopause Society
Address: Wulf H. Utian, MD, Executive Director, The North American Menopause Society, 5900 Landerbrook Drive, Cleveland, OH 44124; e-mail: firstname.lastname@example.org
The author has indicated that he has received research support from the Amylin, 3M, Barr Laboratories, Berlex Laboratories, Bristol-Myers Squibb, Byk Gulden, Eli Lilly, Endeavor Pharmaceuticals, Forest Laboratories, Neurocrine Biosciences, Novartis, Novo Nordisk, Organon, Pharmacia, Procter & Gamble, Pfizer, Roche, Sepracor, Solvay Pharmaceuticals, Wyeth, and Yamanouchi USA corporations and serves as a consultant for the Eli Lilly, Endeavor, Pfizer, Berlex, and Warner corporations.
This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.